US$ 20.89
diet drug semaglutide Use of new drugs likely to mushroom— Harvard Gazette Slimming down competition over weight-loss
Description
#ObesityTherapeutics #GLP1 #TernsPharma #ObesityTreatment #ClinicalTrials #MetabolicHealth Terns Pharmaceuticals Halts Obesity Program After Underwhelming Phase 2 Data for Oral GLP-1 (TERN-601) Terns Pharmaceuticals announced topline 12-week Phase 2 FALCON results for its once-daily oral GLP-1 receptor agonist TERN-601 in adults with obesity (BMI 2750 kg/m, without diabetes), showing modest placebo-adjusted weight loss of 4.6%, below internal efficacy targets

No grupo que recebeu placebo, a queda foi menor, de 0,8%

Share your reality, join the YouGov panel, and get paid to share your thoughts

Medicine Center Pharmacy prepares sublingual formulations only, consistent with our non-sterile compounding accreditation

Learn more Podcast In this Metabolic Mind episode, neurologic researcher Dr
Parkinsons disease and systemic inflammation
